Arcus Biosciences (RCUS) Competitors $16.64 +2.04 (+13.95%) Closing price 10/13/2025 03:59 PM EasternExtended Trading$16.84 +0.20 (+1.22%) As of 10/13/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. PCVX, MTSR, KRYS, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, and ZLABShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors Vaxcyte Metsera Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Arcus Biosciences (NYSE:RCUS) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Do institutionals & insiders believe in RCUS or PCVX? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, RCUS or PCVX? Arcus Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M6.86-$283M-$3.17-5.25VaxcyteN/AN/A-$463.93M-$4.11-10.66 Is RCUS or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Vaxcyte's return on equity of -16.85% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-109.56% -55.96% -25.73% Vaxcyte N/A -16.85%-15.92% Does the media prefer RCUS or PCVX? In the previous week, Arcus Biosciences had 11 more articles in the media than Vaxcyte. MarketBeat recorded 18 mentions for Arcus Biosciences and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Arcus Biosciences' score of 0.20 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Vaxcyte 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RCUS or PCVX? Arcus Biosciences currently has a consensus price target of $26.78, indicating a potential upside of 60.95%. Vaxcyte has a consensus price target of $106.25, indicating a potential upside of 142.52%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more volatility and risk, RCUS or PCVX? Arcus Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. SummaryVaxcyte beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.55B$3.36B$6.05B$21.48BDividend YieldN/A2.31%5.73%3.67%P/E Ratio-5.2522.0885.3129.66Price / Sales6.86478.69601.4686.18Price / CashN/A44.9825.7717.79Price / Book3.1410.3812.674.63Net Income-$283M-$52.47M$3.32B$1.01B7 Day Performance18.71%0.18%-0.05%-0.80%1 Month Performance44.67%13.95%8.73%0.55%1 Year Performance-7.78%20.83%78.85%13.03% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences1.9677 of 5 stars$16.64+14.0%$26.78+61.0%-9.4%$1.55B$258M-5.25500News CoverageAnalyst ForecastGap UpPCVXVaxcyte2.3013 of 5 stars$41.21-3.4%$106.25+157.8%-61.7%$5.54BN/A-10.03160MTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081KRYSKrystal Biotech4.4962 of 5 stars$180.57-1.5%$209.00+15.7%+3.4%$5.31B$359.21M36.70210Analyst RevisionPTCTPTC Therapeutics3.2633 of 5 stars$64.80-0.9%$69.00+6.5%+69.4%$5.19B$1.76B9.301,410Analyst RevisionARWRArrowhead Pharmaceuticals4.0189 of 5 stars$37.50+3.8%$43.14+15.0%+96.6%$4.99B$3.55M-29.30400ACLXArcellx2.0189 of 5 stars$84.38-0.8%$114.31+35.5%+0.0%$4.72B$107.94M-24.6780Analyst RevisionKYMRKymera Therapeutics1.3652 of 5 stars$57.55-0.6%$61.26+6.5%+33.0%$4.14B$47.07M-16.58170PTGXProtagonist Therapeutics1.6737 of 5 stars$64.14-1.1%$68.36+6.6%+75.6%$4.03B$434.43M91.63120Analyst ForecastCRNXCrinetics Pharmaceuticals3.7167 of 5 stars$41.68+2.0%$74.45+78.6%-16.4%$3.85B$1.04M-10.14210ZLABZai Lab2.5957 of 5 stars$33.31-1.3%$56.35+69.2%+23.3%$3.77B$398.99M-16.331,869News CoveragePositive News Related Companies and Tools Related Companies Vaxcyte Competitors Metsera Competitors Krystal Biotech Competitors PTC Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Arcellx Competitors Kymera Therapeutics Competitors Protagonist Therapeutics Competitors Crinetics Pharmaceuticals Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
